At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 103 enrolled
Drug / intervention
Latanoprost Ophthalmic Productdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicentric Study to Evaluate the Efficacy and Tolerability of an Innovative Formulation of Benzalkonium Chloride-free Latanoprost in Patients With Primary Open-Angle Glaucoma
In Brief
A Phase 4 clinical trial evaluating Latanoprost Ophthalmic Product for Primary Open-angle Glaucoma. Completed, enrolled 103 participants across 1 site.
Detailed Summary
This study evaluates the efficacy and tolerability of a new formulation of latanoprost without Benzalkonium Chloride (BAK-free). Patients with open-angle glaucoma who were using BAK-containing latanoprost ophthalmic solution for ≥6 months, switched to BAK-free latanoprost ophthalmic emulsion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Open-angle Glaucoma
CountriesArgentina
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
Primary CompletionOct 2017
First PostedNov 2017
TodayJul 2026
First PostedNov 6, 2017
Enrollment StartJan 6, 2017
Primary CompletionOct 6, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.7 years ago
Interventions
Latanoprost Ophthalmic Productdrug
Multidose bottle, preserved with potassium sorbate, that can be stored at room temperature up to 30°C during all shelf life, the emulsion does not require shaking before use